Connect Biopharma Holdings Limited (CNTB)
|Net Income (ttm)||-119.15M|
|Trading Day||April 9|
|Day's Range||16.22 - 17.15|
|52-Week Range||15.29 - 23.29|
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma...
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bioph...
Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Op...
SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improvi...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.
SAN DIEGO and TAICANG, China, March 18, 2021 -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage...
Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Connect Biopharma Holdings Limited has filed to go public with an IPO on the NASDAQ.
Connect Biopharma is a global clinical-stage biopharmaceutical company developing therapies for the treatment of inflammatory diseases with significant unmet medical need. We specialize in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. We have initiated a Phase 2b tr... [Read more...]
|IPO Date |
Mar 19, 2021
Zheng Wei, Ph.D.
|Stock Exchange |
|Ticker Symbol |